Kemp Dolliver

Stock Analyst at Brookline Capital

(0.27)
# 4,197
Out of 4,893 analysts
15
Total ratings
25%
Success rate
-29.34%
Average return

Stocks Rated by Kemp Dolliver

Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $4.44
Upside: +282.88%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.82
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.84
Upside: +330.93%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.44
Upside: +1,375.41%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.95
Upside: +1,510.26%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $3.73
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $83.49
Upside: +19.77%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.11
Upside: +2,607.84%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $3.46
Upside: +622.54%
electroCore
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $7.98
Upside: +134.96%
Assumes: Buy
Price Target: $8
Current: $0.69
Upside: +1,062.12%
Initiates: Buy
Price Target: $5.65
Current: $1.06
Upside: +433.02%